Improving the production of lentiviral vectors for therapies
LentiSAFE Ligands: Mild-Elution Immunoaffinity Ligands for Enrichment and Purification of Lentiviral Vectors
This study is working on better ways to make and clean up special tools called lentiviral vectors that help with gene therapy, so that they can be produced more easily and safely for people who need them.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mabswitch, INC. NIH-funded |
| Lab location | 1 site (Van Nuys, United States) |
| Project ID | NIH-10819606 on NIH RePORTER |
What this research studies
This research focuses on developing new methods to produce lentiviral vectors, which are important tools for gene therapy. The project aims to create a more efficient and scalable process for purifying these vectors, ensuring they meet the high-quality standards required for clinical use. By using innovative ligands that allow for gentle purification, the researchers hope to overcome current challenges that lead to the degradation of these fragile viral particles. This work could significantly enhance the availability of lentiviral vectors for various therapeutic applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who may benefit from gene therapies that utilize lentiviral vectors for treatment.
Not a fit: Patients who are not candidates for gene therapy or those with conditions that do not involve lentiviral vector treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective gene therapies by providing a reliable supply of high-quality lentiviral vectors.
How similar studies have performed: While there have been advancements in the purification of other viral vectors, this approach for lentiviral vectors is relatively novel and has not been extensively tested.
Where this research is happening
Van Nuys, United States
- Mabswitch, INC. — Van Nuys, United States (Active)
Researchers
- Principal investigator: Onakunle, Yemi — Mabswitch, INC.
- Study coordinator: Onakunle, Yemi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.